Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-06-07
1998-12-01
Schwadron, Ronald B.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241431, 4241441, 4241531, 4241551, 4241731, 4241741, 424 149, 424800, 424801, 424 937, 5303873, 53038822, 53038873, 5303888, 5303897, 5303913, 530804, 530867, 435328, 435334, 4353431, 435344, 435354, A61K 3900, A61K 39395, A61K 5100, C07K 1630
Patent
active
058434399
ABSTRACT:
Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
REFERENCES:
patent: 5500362 (1996-03-01), Robinson et al.
Anderson et al., The Second Annual IBC Int. Conference on Antibody Engineering, Dec. 16-18, 1991.
Grosshard et al., Blood, 80:863-878, 1992.
Anderson Darrell R.
Hanna Nabil
Leonard John E.
Newman Roland A.
Rastetter William H.
LandOfFree
Therapeutic application of chimeric and radiolabeled antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic application of chimeric and radiolabeled antibodies , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic application of chimeric and radiolabeled antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2393375